Skip to content

Alto Neuroscience ANRO Operating Lease ROU Assets

Operating Lease ROU Assets at other companies

Xenon Pharmaceuticals logo
Xenon PharmaceuticalsXENE
$6.29M-17.4%
Acadia Pharmaceuticals logo
Acadia PharmaceuticalsACAD
$46.27M-8.6%
Rapport Therapeutics, Inc. logo
Rapport Therapeutics, Inc.RAPP
$9.33M+24.9%
Praxis Precision Medicines, Inc. logo
Praxis Precision Medicines, Inc.PRAX
$1.32M+49.7%
MeiraGTx Holdings plc logo
MeiraGTx Holdings plcMGTX
$12.12M+91.0%
LBR
LB Pharmaceuticals Inc Common StockLBRX
$2.1M

Other financials

Income statement

See full
Operating income-$27.1M-73.1%
Net income-$26.2M-73.0%
EPS (diluted)-$0.80-42.9%

Balance sheet

See full
Cash & equivalents$264.3M+63.9%
Total debt$20.9M-17.2%
Total equity$243.4M+75.0%
Total assets$276.3M+60.7%

Cash flow

See full
Operating cash flow-$27.1M-63.6%
CapEx$556.0K+2,217%
Free cash flow-$27.6M-66.7%

Valuation

See full
Market cap$874.19M+1,358%
Enterprise value$630.81M-958%

Returns & leverage

See full
Return on equity-38.9%+0.9pp
Debt / equity0.1×-0.1×
Current ratio20.5×-2.0×

Where this comes from

Reported directly by Alto Neuroscience in its filing.

Tagged under the XBRL concept us-gaap:OperatingLeaseRightOfUseAsset.

The official record: Alto Neuroscience’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Alto Neuroscience's operating lease rou assets.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Alto Neuroscience's operating lease ROU assets?
Alto Neuroscience (ANRO) reported operating lease ROU assets of $4.06M in Q1 2026.
How has Alto Neuroscience's operating lease ROU assets changed year-over-year?
Alto Neuroscience's operating lease ROU assets decreased by 16.2% year-over-year, from $4.85M to $4.06M.
What does operating lease ROU assets mean?
Right-of-use assets representing the lessee's right to use leased property over the lease term under ASC 842 operating lease classification.